RHHVF
Roche Holding AG
OTC Markets OTCQXUSDEQUITY
Healthcare
DELAYED
Last price
468.60
▲ 10.09 (2.20%)
MARKET · —
Price
Open
465.60
Prev close
458.51
Day high
467.65
Day low
465.60
Volume
45
Market cap
$373.36B
P/E (TTM)
24.93
52W range
314.15 – 490.33
Trailing performance
Returnvs SPY
1W
+8.08%
+9.4%
1M
+9.47%
+5.7%
3M
+10.87%
+7.8%
6M
-2.37%
-13.4%
YTD
+13.48%
+1.2%
1Y
+42.81%
+22.8%
3Y
+57.91%
-16.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$373.36B
Enterprise value$400.96B
Revenue (TTM)$62.96B
Gross profit$46.69B
EBITDA$23.96B
Net income$12.34B
EPS (TTM)$18.80
Free cash flow$10.32B
Total cash$9.73B
Total debt$33.31B
Book value / share$50.63
Shares outstanding690.07M
Float654.09M
Short % of float—
Dividend yield2.65%
Beta (5Y)0.35
Valuation & profitability ratios
Trailing P/E24.93
Forward P/E17.60
PEG ratio1.68
Price / sales—
Price / book9.26
EV / revenue6.37
EV / EBITDA16.73
Gross margin74.17%
Operating margin36.20%
Profit margin19.60%
Return on equity38.11%
Return on assets13.51%
Debt / equity90.72
Current ratio1.23
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $61.52B | $60.49B | $58.72B | $63.28B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $12.88B | $8.28B | $11.50B | $12.42B |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $12.88B | $8.28B | $11.50B | $12.42B |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $15.57B | +4.3% |
| Next quarter | — | — | $16.17B | +3.3% |
| Current year | 20.10 | 1 | $62.64B | +1.8% |
| Next year | 21.29 | 1 | $65.47B | +4.5% |
Analyst targets & ownership
Mean target$474.50
High target$474.50
Low target$474.50
Implied upside1.26%
Analyst count1
ConsensusNONE
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders0.00%
Held by institutions44.00%
Institutions holding1.07K
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Moving averages & technicals
SMA 10
451.42
+3.81% from price
SMA 20
448.88
+4.39% from price
SMA 50
426.29
+9.93% from price
SMA 100
415.55
+12.77% from price
SMA 200
416.34
+12.55% from price
EMA 12
451.91
+3.69% from price
EMA 26
442.79
+5.83% from price
EMA 50
432.61
+8.32% from price
RSI (14)
62.0
Neutral
MACD (12,26,9)
9.11
Hist 0.56
ATR (14)
19.11
4.08% of price
Realised vol 30D
37.4%
Annualised
Bollinger upper
468.26
20, 2σ
Bollinger lower
429.49
20, 2σ
50 / 200 cross
Golden
426.29 vs 416.34
Trend bias
Above 200
+12.55%
Risk profile
Beta vs SPY
0.13
Less volatile than market
Correlation to SPY
0.04
Largely independent
Realised vol 30D
37.4%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-23.9%
Peak to trough
Max drawdown 5Y
-45.1%
Peak to trough
ATR 14
19.11
4.08% of price
Beta (reported)
0.35
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Is Roche Holding (SWX:ROP) Fully Valued After Its Latest US Manufacturing Push?
Simply Wall St. · 19h ago
Roche commits $750m to double Oregon-based US manufacturing capacity
Pharmaceutical Technology · 1d ago
Roche (SWX:ROP) Stock Could Be Below Fair Value After US Manufacturing Expansion
Simply Wall St. · 1d ago
Roche’s US subsidiary Genentech announces manufacturing expansion in the United States
GlobeNewswire · 2d ago
Analog Devices Q3 Earnings Call Highlights AI Power Growth Runway
Zacks · 2d ago
Genentech Announces Manufacturing Expansion in Hillsboro, Oregon
Business Wire · 2d ago
Why Is Merck Stock Still Undervalued After An 80% Surge?
Trefis · 2d ago
Real Parkinson’s Disease Hope from Jupiter Neurosciences
Exec Edge · 3d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.